Bristol-Myers Squibb beat second quarter earnings estimates, while also lifting its full-year profit guidance.
The pharmaceutical company’s non-GAAP earnings for the three months ending in June came in at $1.18 per share, 10 cents higher than the Street consensus estimates. The earnings per share figure is also +16.8% higher compared to the year-ago quarter.
The company’s total revenues increased +10.52% to $6.3 billion, topping analysts' estimates of $5.72 billion. Sales from Its blood clot treatment Eliquis surged +24% to touch to $2.04 billion.
For the full-year 2019, Bristol-Myers said that it would lower its GAAP earnings guidance by around 10 cents per share, to a range of $3.73 to $3.83 per share. Nevertheless, the company boosted its non-GAAP by 10 cents to, a new range of $4.20 to $4.30 per share.
BMY saw its Momentum Indicator move above the 0 level on January 15, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on January 21, 2025. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
BMY moved above its 50-day moving average on January 21, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on January 27, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for BMY moved out of overbought territory on January 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
BMY broke above its upper Bollinger Band on January 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.642) is normal, around the industry mean (5.632). P/E Ratio (13.728) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.404) is also within normal values, averaging (3.004). Dividend Yield (0.044) settles around the average of (0.164) among similar stocks. P/S Ratio (2.447) is also within normal values, averaging (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor